Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3258084 | 1.00 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2SIGMAR1EPHX1NAAA | |
| SCHEMBL5541866 | 1.00 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2SIGMAR1EPHX1NAAA | |
| SCHEMBL5543667 | 0.98 | SMN1; SMN2 (0.41) | CYP1A2SMN1; SMN2SIGMAR1EPHX1NAAA | |
| SCHEMBL5536432 | 0.94 | EPHX1 (0.47) | CYP1A2SMN1; SMN2SIGMAR1EPHX1NAAA | |
| SCHEMBL5545358 | 0.94 | SMN1; SMN2 (0.38) | CYP1A2SMN1; SMN2SIGMAR1EPHX1NAAA | |
| SCHEMBL5547908 | 0.92 | SIGMAR1 (0.48) | CYP1A2SMN1; SMN2SIGMAR1EPHX1NAAA | |
| SCHEMBL5535566 | 0.92 | SIGMAR1 (0.48) | CYP1A2SMN1; SMN2SIGMAR1EPHX1NAAA | |
| SCHEMBL5546605 | 0.89 | — | — | |
| SCHEMBL5535368 | 0.88 | EPHX1 (0.41) | CYP1A2SMN1; SMN2SIGMAR1EPHX1NAAA | |
| SCHEMBL5543962 | 0.87 | NFE2L2 (0.39) | CYP1A2SMN1; SMN2SIGMAR1EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0392317-A2 | Benzimidazoles, drugs containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP1A2 659/4885SMN1; SMN2 3985/4885SIGMAR1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.